LONG® EGF is a recombinant analogue of human epidermal growth factor (EGF) developed as a supplement for use in therapeutic cell culture applications as a like for-like replacement for native EGF or recombinant human EGF (rhEGF). It comprises the human EGF amino acid sequence plus a 53 amino acid N-terminal extension peptide.
LONG® EGF has applications in MSC, iPS, epithelial, fibroblast, HEK293, BHK-21, and MDCK cell lines. LONG® EGF may also exhibit synergistic effects with LONG®R3 IGF-I in certain cell lines.
Yes. LONG® EGF is manufactured according to cGMP standards. The production facility is regularly audited by European and US contract manufacturers and biopharmaceutical companies.
LONG® EGF is regulatory compliant and is currently used in the manufacture of regulatory approved and marketed cell therapies.
No. LONG® EGF is a cGMP grade recombinant protein produced in E. coli. It is specifically manufactured for mammalian cell culture using a process that is free of animal-derived components.
The recommended concentration range is 10 - 50 μg/l. The maximum should not exceed 100 μg/l and generally lower concentrations work better than higher ones. As a starting point, we recommend developing a media with 50 μg/l.
We do not recommend dissolving freeze-dried formulations in media.
Concentrations of 1mg/ml or more are recommended.
As with all peptides, LONG® EGF can stick to plumbing and filters in the absence of other protein components. We recommend that the supplemented media be sterile filtered with a low protein binding filter prior to use.